NMN

NMN is nicotinamide mononucleotide, one step from NAD, and it sits in longevity stacks because oral doses do raise NAD-related markers in blood. The trials are small and the results are mixed in an instructive way. Twelve weeks at 250mg a day in 36 healthy middle-aged adults raised serum nicotinamide and did not move arterial stiffness. A 28-day study using a pharmaceutical-grade NMN at 1000mg twice daily in 30 overweight or obese adults saw body weight, diastolic blood pressure and LDL fall, and saw no change in insulin sensitivity, liver fat or muscle strength. Doses across the literature run from 250 to 1200mg a day over four to twelve weeks. Human safety data is thin rather than reassuring, no interaction studies exist, and the US regulatory position has been unsettled since 2022 because the same molecule is under investigation as a drug.

Stack Almanac records your NMN dose and the date you started next to everything else you take, which is the minimum you need before you can say whether the spend is buying you anything.